Altimmune ALT Deferred Offering Costs In Accrued Expenses And Other Current Liabilities
Deferred Offering Costs In Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept alt:DeferredOfferingCostsInAccruedExpensesAndOtherCurrentLiabilities.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's deferred offering costs in accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's deferred offering costs in accrued expenses and other current liabilities?
- Altimmune (ALT) reported deferred offering costs in accrued expenses and other current liabilities of $173K in Q1 2025.
- What does deferred offering costs in accrued expenses and other current liabilities mean?
- This represents the portion of costs related to future or past capital offerings that have been accrued but not yet paid in cash. It reflects liabilities incurred for services like investment banking, legal, or registration fees associated with financing activities. Tracking this helps identify upcoming cash obligations related to capital market transactions.